No Data
No Data
Analysts Are Bullish on These Healthcare Stocks: 89bio (ETNB), Perspective Therapeutics (CATX)
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status
89bio (ETNB) said Wednesday its investigational liver disease drug pegozafermin has received the Priority Medicines, or PRIME, status from the European Medicines Agency. The company said the PRIME sta
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) With Fibrosis and Compensated Cirrhosis
PDF Version –PRIME status is supported by positive data from the Phase 2b ENLIVEN trial of pegozafermin––Phase 3 ENLIGHTEN-Fibrosis trial in non-cirrhotic MASH (fibrosis stage F2-F3) patients is
Inventiva Phase 2 Study for MASH Drug Meets Primary Endpoint
The NASH pharmaceutical market is expected to exceed $48 billion by 2035, and companies such as Novo Nordisk (NVO.US) and Lily.US (LLY.US) will begin to deploy
According to international consulting firm Research Nester, the global non-alcoholic steatohepatitis (NASH) treatment market is expected to reach US$48.3 billion by 2035.
NASH Drug Market Expected to Surpass $48B by 2035
No Data